3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
1
Interventions
Capecitabine
16
Paclitaxel
12
Docetaxel
10
Cyclophosphamide
10
Epirubicin
8
Gemcitabine
7
Letrozole
6
Doxorubicin
6
Carboplatin
6
Trastuzumab
5
Vinorelbine
4
Cisplatin
4
pertuzumab
3
exemestane
3
Neoadjuvant Therapy
3
Drug Therapy
3
Ado-Trastuzumab Emtansine
3
AC protocol
3
130-nm albumin-bound paclitaxel
3
apatinib
2
Zoledronic Acid
2
Thiotepa
2
Taxes
2
Tamoxifen
2
Standard of Care
2
Radiosurgery
2
Melatonin
2
Lapatinib
2
Injections
2
Goserelin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Breast Neoplasms
×
gancotamab
×
Clear all
NCT02213744
2017-01-06
HERMIONE
Merrimack Pharmaceuticals
Phase 2/3
Terminated
113 enrolled